Imperial College London
Alternate

ProfessorMarkThursz

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Hepatology. Head of Department
 
 
 
//

Contact

 

+44 (0)20 3312 1903m.thursz

 
 
//

Assistant

 

Ms Dawn Campbell +44 (0)20 3312 6454

 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Yusuke:2018:10.1016/j.jhep.2018.05.024,
author = {Yusuke, S and Njie, R and Ndow, G and Vray, M and Mbaye, PS and Bonnard, P and Sombie, R and Nana, J and Leroy, V and Bottero, J and Ingiliz, P and Post, G and Sanneh, B and Baldeh, I and Suso, P and Ceesay, A and Jeng, A and Njai, HF and Nayagam, S and D'Alessandro, U and Chemin, I and Mendy, M and Thursz, M and Lemoine, M},
doi = {10.1016/j.jhep.2018.05.024},
journal = {Journal of Hepatology},
pages = {776--784},
title = {Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa},
url = {http://dx.doi.org/10.1016/j.jhep.2018.05.024},
volume = {69},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background & AimsTo eliminate hepatitis B virus (HBV) infection, it is essential to scale up antiviral treatment through decentralized services. However, access to the conventional tools to assess treatment eligibility (liver biopsy/Fibroscan/HBV DNA) is limited and non-affordable in resource-limited countries. We developed and validated a simple score to easily identify patients in need of HBV treatment in Africa.MethodsAs a reference, we used treatment eligibility determined by the European Association for the Study of the Liver (EASL) based on alanine transaminase (ALT), liver histology and/or Fibroscan and HBV DNA. We derived a score indicating treatment eligibility by a stepwise logistic regression using a cohort of chronic HBV infection in The Gambia (n=804). We subsequently validated the score in an external cohort of HBV-infected Africans from Senegal, Burkina Faso, and Europe (n=327).ResultsOut of several parameters, two remained in the final model, namely HBV e antigen (HBeAg) and ALT level, and constituted a simple score (TREAT-B). The score demonstrated a high area under the receiver operating characteristic (0.85, 95% CI: 0.79-0.91) in the validation set. The score of 2 and above (HBeAg-positive and ALT≥20 U/L or HBeAg-negative and ALT≥40 U/L) had a sensitivity and specificity for treatment eligibility of 85% and 77%, respectively. The sensitivity and specificity of the WHO criteria based on APRI and ALT were 90% and 40%, respectively. ConclusionsThe diagnostic accuracy of a simple score based on HBeAg and ALT for selecting patients for HBV treatment is high and could be useful in African settings.
AU  - Yusuke,S
AU  - Njie,R
AU  - Ndow,G
AU  - Vray,M
AU  - Mbaye,PS
AU  - Bonnard,P
AU  - Sombie,R
AU  - Nana,J
AU  - Leroy,V
AU  - Bottero,J
AU  - Ingiliz,P
AU  - Post,G
AU  - Sanneh,B
AU  - Baldeh,I
AU  - Suso,P
AU  - Ceesay,A
AU  - Jeng,A
AU  - Njai,HF
AU  - Nayagam,S
AU  - D'Alessandro,U
AU  - Chemin,I
AU  - Mendy,M
AU  - Thursz,M
AU  - Lemoine,M
DO  - 10.1016/j.jhep.2018.05.024
EP  - 784
PY  - 2018///
SN  - 0168-8278
SP  - 776
TI  - Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa
T2  - Journal of Hepatology
UR  - http://dx.doi.org/10.1016/j.jhep.2018.05.024
UR  - https://www.sciencedirect.com/science/article/pii/S0168827818321020?via%3Dihub
UR  - http://hdl.handle.net/10044/1/60058
VL  - 69
ER  -
Download